ACTICOR BIOTECH: Disclosure of the Total Number of Voting Rights and Shares as of January 31, 2024
06 Febbraio 2024 - 6:00PM
Business Wire
Regulatory News:
ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage
biopharmaceutical company developing glenzocimab, an innovative
drug for the treatment of cardiovascular emergencies, today
discloses the total number of voting rights and shares as of
January 31, 2024 (pursuant to Article L. 233-8 II of the French
Commercial Code and Article 223-16 of the General Regulation of the
French Financial Markets Authority).
- Listing Place: Euronext Growth Paris
- ISIN Code : FR0014005OJ5
- Web site: acticor-biotech.com
Date
Number of shares making up the
share capital
Theoretical number of voting
rights (1)
Number of voting rights excluding
shares stripped of voting rights (2)
January 31, 2024
13.189.141
13.189.141
13.134.635
(1) In accordance with Article 223-111 of the AMF’s General
Regulation, this number of shares is calculated based on all shares
carrying the right to vote, including those stripped of voting
rights. (2) The actual voting rights correspond to the total number
of voting rights that can be exercised in a general meeting. They
are calculated on the basis of the total number of voting rights
attached to the total number of shares minus the shares without
voting rights.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a
spin-off from INSERM (the French National Institute of Health and
Medical Research), which is aiming to develop an innovative
treatment for cardiovascular emergencies, including ischemic
stroke.
The positive results of the phase 1b/2a study, ACTIMIS,
published in January 2024 in the Lancet Neurology (link to the
publication), confirmed the safety profile of glenzocimab and
showed a reduction in mortality and intracerebral hemorrhage in the
glenzocimab-treated group of stroke patients. These results were
confirmed by a post-hoc analysis of brain imaging at 0 and 24 hours
using artificial intelligence (Brainomix, UK). This independent
analysis confirmed the reduction in the number and volume of
intracerebral lesions in patients treated with glenzocimab. The
efficacy of glenzocimab is now being analyzed in an international
Phase 2/3 study, ACTISAVE, with clinical results expected in Q2
2024.
In July 2022, Acticor Biotech was granted "PRIME" status by the
European Medicines Agency (EMA) for glenzocimab in the treatment of
stroke. This designation will allow the company to strengthen its
interactions and obtain early dialogues with regulatory
authorities.
Acticor Biotech is supported by a panel of European and
international investors (Mediolanum farmaceutici, Karista, Go
Capital, Newton Biocapital, CMS Medical Venture Investment (HK)
Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation).
Acticor Biotech is listed on Euronext Growth Paris since November
2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206200839/en/
ACTICOR BIOTECH Gilles AVENARD, MD CEO and Founder
gilles.avenard@acticor-biotech.com T. : +33 (0)6 76 23 38
13
Sophie BINAY, PhD General Manager and CSO
Sophie.binay@acticor-biotech.com T. : +33 (0)6 76 23 38
13
NewCap Mathilde BOHIN Investor Relations
acticor@newcap.eu T. : +33 (0)1 44 71 94 95
NewCap Arthur ROUILLÉ Media Relations acticor@newcap.eu
T. : +33 (0)1 44 71 00 15
Grafico Azioni Acticor Biotech (EU:ALACT)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Acticor Biotech (EU:ALACT)
Storico
Da Dic 2023 a Dic 2024
